Similar articles

• [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].

  Mallmann P. Mallmann P. Internist (Berl). 2006 Nov;47(11):1183-5. doi: 10.1007/s00108-006-1720-x. Internist (Berl). 2006. PMID: 17048017 German. No abstract available.
• Why adjuvant trastuzumab led to better outcomes in women with high-risk HER-2-positive breast cancer.

  Altundag K, Baptista MZ. Altundag K, et al. Breast J. 2006 Sep-Oct;12(5):497-8. doi: 10.1111/j.1075-122X.2006.00314.x. Breast J. 2006. PMID: 16958977 No abstract available.
• Trastuzumab before breast surgery? Large trial says yes but does not quell debate.

  Rowan K. Rowan K. J Natl Cancer Inst. 2009 Apr 1;101(7):448-9. doi: 10.1093/jnci/djp072. Epub 2009 Mar 24. J Natl Cancer Inst. 2009. PMID: 19318626 No abstract available.
• Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.

  Baselga J. Baselga J. Oncology. 2001;61 Suppl 2:14-21. doi: 10.1159/000055397. Oncology. 2001. PMID: 11694783 Review.
• Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.

  Baselga J, Perez EA, Pienkowski T, Bell R. Baselga J, et al. Oncologist. 2006;11 Suppl 1:4-12. doi: 10.1634/theoncologist.11-90001-4. Oncologist. 2006. PMID: 16971734 Review.